Trial
NCT03630952
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Chengdu Kanghong Biotech Co., Ltd.
Collaborators
—
Condition
Neovascular Age-related Macular Degeneration
Intervention
0.5 mg Conbercept Intravitreal Injection
Why stopped
desired primary endpoint was not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-23